Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025
Rhea-AI Summary
Cellectar Biosciences (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company specializing in cancer treatment drug development, has scheduled its full year 2024 financial results announcement and corporate update for March 13, 2025, at 8:30 a.m. Eastern Time. The company will make a replay of the conference call available through their Investor Relations website's Events section.
Positive
- None.
Negative
- None.
News Market Reaction – CLRB
On the day this news was published, CLRB gained 6.56%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
FLORHAM PARK, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the company will report financial results for the full year ended December 31, 2024, and provide a corporate update on March 13, 2025, at 8:30 a.m. Eastern Time.
| Conference Call & Webcast Details: | |
| Date: | Thursday, March 13, 2025 |
| Time: | 8:30 am Eastern Time |
| Toll Free: | 1-800-717-1738 |
| Conference ID: Webcast: | 25759 Click HERE |
A replay of the call will be available on the Events section of the company’s Investor Relations website.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.
The company’s product pipeline includes its lead assets: iopofosine I 131, a PDC designed to provide targeted delivery of iodine-131 (radioisotope); CLR 121225, an actinium-225 based program being targeted to several solid tumors with significant unmet need, such as pancreatic cancer; and CLR 121125, an iodine-125 Auger-emitting program targeted in other solid tumors, such as triple negative breast, lung and colorectal, as well as proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.
In addition, iopofosine I 131 has been studied in Phase 2b trials for relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) lymphoma, and the CLOVER-2 Phase 1b study, targeting pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has also granted iopofosine I 131 six Orphan Drug, four Rare Pediatric Drug and two Fast Track Designations for various cancer indications.
For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook.
Investor Contact:
Anne Marie Fields
212-362-1200
Precision AQ (formerly Stern IR)
annemariefields@precisionaq.com
FAQ
When will Cellectar Biosciences (CLRB) release its 2024 annual financial results?
How can investors access CLRB's 2024 annual earnings call replay?
What is the main business focus of Cellectar Biosciences (CLRB)?
What time is CLRB's 2024 annual earnings conference call scheduled for?
